

1 **Efficacy of a novel SARS-CoV-2 detection kit without RNA extraction and**  
2 **purification**

3

4 **Running title**

5 A novel SARS-CoV-2 detection kit

6

7 Tatsuya Fukumoto PhD<sup>1\*</sup>, Sumio Iwasaki<sup>1\*</sup>, Shinichi Fujisawa<sup>1</sup>, Kasumi Hayasaka<sup>1</sup>, Kaori  
8 Sato<sup>1</sup>, Satoshi Oguri PhD<sup>1</sup>, Keisuke Taki<sup>1</sup>, Sho Nakakubo, MD<sup>2\*</sup>, Keisuke Kamada, MD<sup>2</sup>,  
9 Yu Yamashita, MD<sup>2</sup>, Satoshi Konno, MD<sup>2</sup>, Mutsumi Nishida, PhD<sup>1</sup>, Junichi Sugita, MD<sup>1,3</sup>,  
10 Takanori Teshima, MD<sup>1,3</sup>

11

12 <sup>1</sup>Division of Laboratory and Transfusion Medicine, Hokkaido University Hospital, Sapporo,  
13 Japan

14 <sup>2</sup>Department of Respiratory Medicine, Hokkaido University Faculty of medicine, Sapporo,  
15 Japan

16 <sup>3</sup>Department of Hematology, Hokkaido University Faculty of medicine, Sapporo, Japan

17

18 \*Equally contributing first author.

19 **Key words:**

20 COVID-19, SARS-CoV-2, Saliva, PCR, 2019 Novel Coronavirus Detection Kit

21 **Correspondence address**

22 Takanori Teshima, M.D., Ph.D.

23 Department of Hematology, Hokkaido University Faculty of Medicine

24 N15 W7, Kita-ku, Sapporo, Hokkaido 060-8638, Japan

25 Telephone: 81-11-706-7214, FAX: 81-11-706-7823

26 E-mail: [teshima@med.hokudai.ac.jp](mailto:teshima@med.hokudai.ac.jp)

27 **Competing Interests**

28 The authors declare that they have no competing interests.

29

30

31 **Abstract**

32 Rapid detection of SARS-CoV-2 is critical for the diagnosis of coronavirus disease 2019  
33 (COVID-19) and preventing the spread of the virus. A novel “2019 Novel Coronavirus  
34 Detection Kit (nCoV-DK)” halves detection time by eliminating the steps of RNA extraction  
35 and purification. We evaluated concordance between the nCoV-DK and direct PCR. The  
36 virus was detected in 53/71 fresh samples by the direct method and 55/71 corresponding  
37 frozen samples by the nCoV-DK. The overall concordance rate of the virus detection  
38 between the two methods was 94.4% (95% CI, 86.2-98.4). Concordance rates were 95.2%  
39 (95% CI, 83.8-99.4), 95.5% (95% CI, 77.2-99.9), 85.7% (95% CI, 42.1-99.6) in  
40 nasopharyngeal swab, saliva, and sputum samples, respectively. These results indicate  
41 that the nCoV-DK effectively detects SARS-CoV-2 in all types of the samples including  
42 saliva, while reducing time required for detection, labor, and risk of human error.

43

44 **Introduction**

45 Rapid and accurate detection of SARS-CoV-2 is critical for the prevention of outbreaks of  
46 coronavirus disease 2019 (COVID-19) in communities and hospitals. The diagnosis of  
47 COVID-19 is made by real-time quantitative PCR (RT-qPCR) testing of specimens  
48 collected by nasopharyngeal or pharyngeal swabs, with the nasopharyngeal route being

49 the standard and sensitivity to the virus ranging from 52% to 71%(1-5). However, swab  
50 sample collection poses a risk of viral transmission to healthcare workers. Self-collecting  
51 saliva specimens are noninvasive tool for the virus detection and reduce a risk of health  
52 care workers. A series of recent studies have shown efficacy of saliva as a diagnostic  
53 tool(6-10). We recently reported 97% concordance rate between nasopharyngeal swab  
54 samples and saliva in the detection of SARS-CoV-2(11).

55

56 The 2019 Novel Coronavirus Detection Kit (nCoV-DK, Shimadzu Corporation, Kyoto,  
57 Japan) is a novel SARS-CoV-2 detection kit, which eliminates the steps of RNA extraction  
58 and purification by using the Ampdirect™ technology(12), thus significantly reducing the  
59 time required for sample preparation and PCR detection from more than 2 hours to about 1  
60 hour. In addition, the risk of human error can be reduced by omitting the manual RNA  
61 extraction. However, nCoV-DK was initially developed for the use of nasopharyngeal swab  
62 specimens and it remained to be elucidated whether saliva samples could be applied to the  
63 nCoV-DK, since saliva has high RNase(13). In this study, we compared efficacy of the  
64 nCoV-DK with the direct PCR method requiring RNA extraction and purification using  
65 nasopharyngeal swab, saliva, and sputum samples.

66

67 **Methods**

68 ***Samples***

69 Nasopharyngeal swab, sputum and saliva samples were collected from 9 patients who  
70 were admitted to our hospital after a diagnosis of COVID-19. A total of 71 samples were  
71 selected for this study according to the availability of the frozen stock samples. This study  
72 was approved by the Institutional Ethics Board and informed consent was obtained from all  
73 patients. Nasopharyngeal samples were obtained using FLOQSwabs (COPAN, Murrieta,  
74 CA, USA). Sputum and saliva samples were self-collected in a sterilized PP Screw cup 50  
75 (Asiakizai Co., Ltd., Tokyo, Japan). 200  $\mu$ L sputum or saliva were added to 600  $\mu$ L PBS,  
76 mixed vigorously, then centrifuged at 20,000 X g for 5 minutes at 4°C, and and the  
77 supernatant was used.

78

79 ***PCR***

80 Direct RT-qPCR was performed according to the manual "Pathogen Detection 2019-nCoV  
81 Ver. 2.9.1" (March 19, 2020) from the National Institute of Infectious Diseases  
82 (<https://www.niid.go.jp/niid/images/lab-manual/2019-nCoV20200319.pdf>, accessed  
83 2020-5-20). Total RNA was extracted using the QIAamp Viral RNA Mini Kit (QIAGEN,  
84 Hilden, Germany) from fresh samples. One-step RT-qPCR was performed using One-Step

85 Real-Time RT-PCR Master Mixes (Thermo Fisher Scientific, Waltham, USA) and the  
86 StepOnePlus Real Time PCR System (Thermo Fisher Scientific) with forward primer  
87 (5'-AAA TTT TGG GGA CCA GGA AC-3), reverse primer (5'-TGG CAG CTG TGT AGG  
88 TCA AC-3'), and TaqMan probe (5'-FAM-ATG TCG CGC ATT GGC ATG GA-BHQ-3').

89

90 The nCoV-DK PCR was carried out using the corresponding frozen specimens used for the  
91 direct PCR detection as above. The samples were processed according to the  
92 manufacturer's instruction. In brief, 5 µL of sample and 5 µL of sample treatment reagent  
93 were mixed and heated for 5 min at 90°C using a thermal cycler to inactivate RNase. After  
94 cooling on ice, 15 µL of the reaction mixture containing primers and polymerase was added.  
95 PCR was performed using the CFX96 Touch Deep Well Real-Time PCR Detection System  
96 (Bio-Rad, California, USA). The nCoV-DK uses the "2019-nCoV\_N1" and "2019-nCoV\_N2"  
97 primer and probe sequences as described in the U.S. CDC's "2019-Novel Coronavirus  
98 Real-time rRT-PCR Panel Primers and Probes ". N1 forward Primer (5'-GAC CCC AAA  
99 ATC AGC GAA AT-3'), N1 reverse Primer (5'-TCT GGT TAC TGC CAG TTG AAT CTG-3')  
100 and N1 Probe (5'-ROX-ACC CCG CAT TAC GTT TGG TGG ACC-BHQ2-3') were used. N2  
101 Forward Primer (5'-TTA CAA ACA TTG GCC GCA AA-3'), N2 Reverse Primer (5'-GCC  
102 CGA CAT TCC GAA GAA-3') and N2 Probe (5'-FAM-ACA ATT TGC CCC CAG CGC TTC

103 AG-BHQ1-3') were used. PCR positivity was defined as positive in either or both methods.

104 Reagents and equipment for the nCoV-DK were provided by Shimadzu Corporation.

105

## 106 ***Statistical analysis***

107 Agreement between nasopharyngeal and saliva samples for the detection ability of

108 SARS-CoV-2 was assessed using Cohen's Kappa. Pearson's correlation coefficient test

109 was performed to identify the relation of the Ct values between the methods. All statistical

110 analyses were performed with EZR (Jichi Medical University, Saitama, Japan), which is a

111 graphic user interface for R (The R Foundation for Statistical Computing, Vienna, Austria).

112 *P-value* of 0.05 was used as the cutoff for statistical significance.

113

## 114 **Results**

115 Seventy-one specimens were tested by the direct PCR and the nCoV-DK. The virus was

116 detected in 53 / 71 fresh samples by the direct PCR and 55 / 71 of the corresponding frozen

117 samples by the nCoV-DK (Table 1). The overall concordance rate of the virus detection

118 between the two methods was 94.4% (95% CI, 86.2-98.4). Interrater reliability of the two

119 methods was strong ( $\kappa=0.85$ ) determined by Cohen's kappa analysis. Concordance rates

120 were 95.2% (95% CI, 83.8-99.4), 95.5% (95% CI, 77.2-99.9), 85.7% (95% CI, 42.1-99.6) in

121 nasopharyngeal swab, saliva, and sputum samples, respectively. Figure 1 shows a scatter  
122 plot presenting a comparison of Ct values in each positive sample between the two  
123 methods. There was a strong correlation between the two methods ( $r = 0.837$ , 95%CI =  
124 0.736–0.902,  $P < 0.01$ ). Significant correlations were also demonstrated in each sample  
125 type (Swab,  $r = 0.82$ , 95%CI = 0.673–0.905,  $P < 0.01$ ; Saliva,  $r = 0.818$ , 95%CI = 0.507–  
126 0.94,  $P < 0.01$ ; Sputum,  $r = 0.945$ , 95%CI = 0.574–0.994,  $P < 0.01$ ).

127

## 128 **Discussion**

129 In this study, we demonstrate that a novel SARS-CoV-2 detection kit nCoV-KD is as  
130 effective as the direct PCR methods in detecting SARS-CoV-2 in all types of the samples  
131 tested including saliva. Particularly, it should be noted that our study demonstrated that  
132 saliva is a reliable tool to detect the virus by the nCoV-KD even without process of RNA  
133 extraction and purification. However, there are some discordant results between the two  
134 methods. The virus was detected only by the direct PCR in one sample, while the virus was  
135 detected only by the nCoV-DK in 3 samples. It is unclear whether these are false-positive or  
136 true positive, since PCR primer sets are not the same between the two methods. In  
137 conclusion, the nCoV-DK has advantage over the direct PCR due to shorter detection time  
138 by eliminating the steps of RNA extraction and purification, without impairing diagnostic



139 accuracy.

## 140 **Acknowledgements**

141 This work was in part supported by grants from Japan Medical Association Research  
142 Institute.

143

## 144 **Competing Interests**

145 The authors declare that they have no competing interests.

146

## 147 **References**

148 1. Wang W, Xu Y, Gao R, Lu R, Han K, Wu G, Tan W. 2020. Detection of SARS-CoV-2  
149 in Different Types of Clinical Specimens. JAMA doi:10.1001/jama.2020.3786.

150 2. Ai T, Yang Z, Hou H, Zhan C, Chen C, Lv W, Tao Q, Sun Z, Xia L. 2020. Correlation  
151 of Chest CT and RT-PCR Testing in Coronavirus Disease 2019 (COVID-19) in  
152 China: A Report of 1014 Cases. Radiology doi:10.1148/radiol.2020200642:200642.

153 3. Zou L, Ruan F, Huang M, Liang L, Huang H, Hong Z, Yu J, Kang M, Song Y, Xia J,  
154 Guo Q, Song T, He J, Yen HL, Peiris M, Wu J. 2020. SARS-CoV-2 Viral Load in  
155 Upper Respiratory Specimens of Infected Patients. N Engl J Med 382:1177-1179.

156 4. Fang Y, Zhang H, Xie J, Lin M, Ying L, Pang P, Ji W. 2020. Sensitivity of Chest CT for

157 COVID-19: Comparison to RT-PCR. Radiology

158 doi:10.1148/radiol.2020200432:200432.

159 5. Guo L, Ren L, Yang S, Xiao M, Chang, Yang F, Dela Cruz CS, Wang Y, Wu C, Xiao Y,  
160 Zhang L, Han L, Dang S, Xu Y, Yang Q, Xu S, Zhu H, Xu Y, Jin Q, Sharma L, Wang L,  
161 Wang J. 2020. Profiling Early Humoral Response to Diagnose Novel Coronavirus  
162 Disease (COVID-19). Clin Infect Dis doi:10.1093/cid/ciaa310.

163 6. To KK, Tsang OT, Chik-Yan Yip C, Chan KH, Wu TC, Chan JMC, Leung WS, Chik  
164 TS, Choi CY, Kandamby DH, Lung DC, Tam AR, Poon RW, Fung AY, Hung IF, Cheng  
165 VC, Chan JF, Yuen KY. 2020. Consistent detection of 2019 novel coronavirus in  
166 saliva. Clin Infect Dis doi:10.1093/cid/ciaa149.

167 7. To KK, Tsang OT, Leung WS, Tam AR, Wu TC, Lung DC, Yip CC, Cai JP, Chan JM,  
168 Chik TS, Lau DP, Choi CY, Chen LL, Chan WM, Chan KH, Ip JD, Ng AC, Poon RW,  
169 Luo CT, Cheng VC, Chan JF, Hung IF, Chen Z, Chen H, Yuen KY. 2020. Temporal  
170 profiles of viral load in posterior oropharyngeal saliva samples and serum antibody  
171 responses during infection by SARS-CoV-2: an observational cohort study. Lancet  
172 Infect Dis 20:565-574.

173 8. Azzi L, Carcano G, Gianfagna F, Grossi P, Gasperina DD, Genoni A, Fasano M,  
174 Sessa F, Tettamanti L, Carinci F, Maurino V, Rossi A, Tagliabue A, Baj A. 2020.

175 Saliva is a reliable tool to detect SARS-CoV-2. J Infect

176 doi:10.1016/j.jinf.2020.04.005.

177 9. Wyllie AL, Fourmier J, Casanovas-Massana A, Campbell M, Tokuyama M,

178 Vijayakumar P, Geng B, Muenker MC, Moore AJ, Vogels CBF, Petrone ME, Ott IM,

179 Lu P, Lu-Culligan A, Klein J, Venkataraman A, Earnest R, Simonov M, Datta R,

180 Handoko R, Naushad N, Sewanan LR, Valdez J, White EB, Lapidus S, Kalinich CC,

181 Jiang X, Kim DJ, Kudo E, Linehan M, Mao T, Moriyama M, Oh JE, Park A, Silva J,

182 Song E, Takahashi T, Taura M, Weizman O-E, Wong P, Yang Y, Bermejo S, Odio C,

183 Omer SB, Dela Cruz CS, Farhadian S, Martinello RA, Iwasaki A, Grubaugh ND, Ko

184 AI. 2020. Saliva is more sensitive for SARS-CoV-2 detection in COVID-19 patients

185 than nasopharyngeal swabs. medRxiv

186 doi:<https://doi.org/10.1101/2020.04.16.20067835>.

187 10. Williams E, Bond K, Zhang B, Putland M, Williamson DA. 2020. Saliva as a

188 non-invasive specimen for detection of SARS-CoV-2. J Clin Microbiol

189 doi:10.1128/JCM.00776-20.

190 11. Iwasaki S, Fujisawa S, Nakakubo S, Kamada K, Yamashita Y, Fukumoto T, Sato K,

191 Oguri S, Taki K, Senjo H, Hayasaka K, Konno S, Nishida M, Teshima T. 2020.

192 Comparison of SARS-CoV-2 detection in nasopharyngeal swab and saliva. medRxiv

193 doi:<https://doi.org/10.1101/2020.05.13.20100206>.

194 12. Nishimura N, Nakayama H, Yoshizumi S, Miyoshi M, Tonoike H, Shirasaki Y, Kojima  
195 K, Ishida S. 2010. Detection of noroviruses in fecal specimens by direct RT-PCR  
196 without RNA purification. J Virol Methods 163:282-6.

197 13. Pandit P, Cooper-White J, Punyadeera C. 2013. High-yield RNA-extraction method  
198 for saliva. Clin Chem 59:1118-22.

199

200

201

202

### 203 **Figure Legend**

#### 204 **Figure 1. Correlation of Ct values between the direct PCR and nCoV-DK method**

205 A scatter plot shows a comparison of Ct values between the two methods. Negative  
206 samples are denoted with a Ct of 45, which is the limit of detection.

**Table 1. Comparison of SARS-Cov-2 detection in the direct PCR and nCoV-DK method**

nCoV-DK		Direct PCR		kappa (95%CI)
		Positive	Negative	
Total	Positive	52	3	0.85 (0.70-0.99)
	Negative	1	15	
Swab	Positive	34	2	0.83 (0.60-1.00)
	Negative	0	6	
Saliva	Positive	13	0	0.90 (0.72-1.00)
	Negative	1	8	
Sputum	Positive	5	1	0.59 (0-1)
	Negative	0	1	

